Product

Quadrivalent Recombinant influenza vaccine

Aliases

Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH, Supemtek / Flublok Quadrivalent

1 clinical trial

1 indication

Indication

Influenza Immunization

Clinical trial

Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years.

Status: Completed, Estimated PCD: 2023-10-27